Intravenous buprenorphine does not impair psychomotor and cognitive functioning in opioid-dependent patients using oral dextropropoxyphene: A randomized, double-blind, crossover study
S. Goyal, A. Ambekar, R. Jain, M. Mehta, A. Mishra
{"title":"Intravenous buprenorphine does not impair psychomotor and cognitive functioning in opioid-dependent patients using oral dextropropoxyphene: A randomized, double-blind, crossover study","authors":"S. Goyal, A. Ambekar, R. Jain, M. Mehta, A. Mishra","doi":"10.4103/jmhhb.jmhhb_24_20","DOIUrl":null,"url":null,"abstract":"Background and Objectives: Some opioid-dependent injecting buprenorphine (BPN) users can continue to inject BPN even while using dextropropoxyphene as a treatment or as a drug of abuse. With this rationale, this study was aimed to assess the effect of injection BPN on psychomotor and cognitive functioning in opioid-dependent patients receiving oral dextropropoxyphene. Methods: This was a randomized, placebo-controlled, double-blind, crossover study, carried out in the inpatient unit of the tertiary level de-addiction facility. Twenty opioid-dependent male, current injecting drug users were given a single dose of injection of BPN (1.2 mg) or placebo, in a crossover design, 2 h after the routine morning dose of oral dextropropoxyphene at day 4 and day 6 of admission. Psychomotor and cognitive functioning was assessed with the help of standard tools (trail making – Parts A and B, digit symbol substitution test, delayed recall test, and digit span) at baseline and after 10 min, 3 h, and 6 h of injection BPN/placebo. Results: There was no significant difference in the scores on any of the tests for psychomotor and cognitive functioning at any time period after receiving either injection BPN or placebo. Conclusions: A single dose of intravenous BPN in opioid-dependent patients on oral dextropropoxyphene did not produce any significant change in psychomotor and cognitive functioning as compared to placebo.","PeriodicalId":31679,"journal":{"name":"Journal of Mental Health and Human Behaviour","volume":"25 1","pages":"45 - 52"},"PeriodicalIF":0.6000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Mental Health and Human Behaviour","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jmhhb.jmhhb_24_20","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and Objectives: Some opioid-dependent injecting buprenorphine (BPN) users can continue to inject BPN even while using dextropropoxyphene as a treatment or as a drug of abuse. With this rationale, this study was aimed to assess the effect of injection BPN on psychomotor and cognitive functioning in opioid-dependent patients receiving oral dextropropoxyphene. Methods: This was a randomized, placebo-controlled, double-blind, crossover study, carried out in the inpatient unit of the tertiary level de-addiction facility. Twenty opioid-dependent male, current injecting drug users were given a single dose of injection of BPN (1.2 mg) or placebo, in a crossover design, 2 h after the routine morning dose of oral dextropropoxyphene at day 4 and day 6 of admission. Psychomotor and cognitive functioning was assessed with the help of standard tools (trail making – Parts A and B, digit symbol substitution test, delayed recall test, and digit span) at baseline and after 10 min, 3 h, and 6 h of injection BPN/placebo. Results: There was no significant difference in the scores on any of the tests for psychomotor and cognitive functioning at any time period after receiving either injection BPN or placebo. Conclusions: A single dose of intravenous BPN in opioid-dependent patients on oral dextropropoxyphene did not produce any significant change in psychomotor and cognitive functioning as compared to placebo.